Right ventricular failure following left ventricular assist devices implantation is a serious complication associated with high mortality. In patients with or at high risk of developing right ventricular failure, biventricular support is recommended. Because univentricular support is associated with high survival rates, biventricular support is often undertaken as a last resort. With the advent of newer right ventricular and biventricular systems under design and testing, better differentiation is required to ensure optimal patients care. Clear guidelines on patient selection, time of intervention and device selection are required to improve patient outcomes.
The use of left ventricular assist devices (LVADs) in patients with advanced heart failure is well established; they make up 90% of all implanted continuous flow ventricular assist devices (VADs). 1 In advanced heart failure, they are superior to medical therapy alone, 1 with improvements demonstrated in survival, quality of life and functional status in carefully selected patients. 2, 3 Although initially designed as a bridge to cardiac transplantation, they have been reportedly used as destination therapy in 46% of cases, while 23% are implanted in anticipation of potential cardiac transplantation (bridge to candidacy). 1 A significant limitation of LVADs is the lack of corresponding right heart support, which results in one-third of patients developing clinical right heart failure after LVAD implantation. 4, 5 Because there was some early success in these very sick patients, studies have evaluated applicability of VADs in a biventricular configuration (dual LVAD therapy) -one to support the left ventricle (LV) and another to support the right ventricle (RV). [6] [7] [8] [9] [10] Compared with traditional pulsatile biventricular assist device (BiVAD) systems, dual VAD therapy has demonstrated improved survival rates and fewer adverse events, and enabled hospital discharge. [6] [7] [8] [9] [10] Despite this, better outcomes continue to be achieved with isolated LVADs, producing an environment where durable BiVAD are only undertaken in irretrievable cases. 1, 12 To date, biventricular support has been offered to patients unsuitable for isolated LVAD therapy who have pre-existing, right heart failure or impairment and who are thought unlikely to improve after LVAD implantation.
It is important to recognise that those requiring biventricular support are a different population from patients who undergo univentricular support. These patients are generally sicker, with more profound multiple organ dysfunction than those requiring LVAD. Implanting
LVADs into a patient with concomitant right ventricular failure (RVF) or at risk of developing RVF is associated with high mortality. 
Impact of an Left Ventricular Assist Devices on the Right Ventricle
The development of RVF is multifactorial and may not become apparent until after LVAD implantation. A healthy RV is responsible for delivering blood through the lungs and to the left ventricle. The inability to perform such an action can result in inadequate blood delivery to the left ventricle and therefore a decreased delivery of oxygenated blood to the tissue and organs. 23 While the LVAD can improve left ventricular activity, it does not directly aid the RV to pump blood to the lungs. However, the LVAD can indirectly influence the RV by affecting factors such as venous return, septal motion and pulmonary artery pressure. 24 In severe secondary pulmonary hypertension, the use of an LVAD has been shown to relieve pulmonary pressure and decrease right ventricular afterload. 25 This is achieved by increasing forward flow to the body, thereby decreasing right ventricular afterload. However, the increased cardiac output created by the LVAD may overwhelm the load-sensitive RV. Moreover, by decreasing intraventricular LV pressure, the use of the LVAD forces the wall of the septum to shift towards the left, with altered RV geometry resulting in RVF because of decreased RV contractility and reduced RV compliance. 
Time of Intervention
In addition to selecting the correct patients for isolated LVAD or BiVAD support, great consideration must also be given to selecting patients with sufficient severity of illness to achieve a benefit while avoiding those who are too ill or too early in the disease course to derive any gain. rates compared to delayed RVAD support. 37 These findings are also supported in recent durable BiVAD studies, which strongly favoured planned BiVAD support. 7 While BiVAD recipients have greater mortality and morbidity than LVAD recipients, survival following cardiac transplantation does not appear to be associated with the type of configuration used (LVAD versus BiVAD). 38 Therefore, as long as BiVAD recipients are successfully bridged to cardiac transplantation, they will have similar post-transplant survival rates as their LVAD counterparts.
As the pathology of biventricular failure is largely associated with poor systemic blood circulation, it is logical to assume that early intervention with durable BiVADs can reduce mortality rates during the early postoperative period and therefore increase the number of successfully bridged candidates. The challenge then will be to determine the difference between early and too early.
Device Selection
The system, the connection to the descending aorta has made its removal during subsequent heart transplantation difficult, extending both surgical and cardiopulmonary bypass time. 39 Other devices, such as the HeartWare HVAD, can be used for RV support but require minor modifications to implantation technique. 6, 7, 9 The HVAD inflow cannula is too long for the dimension of the RV and, Short-term RVAD support has been successfully performed with various VAD models yielding similar results to long-term BiVAD outcomes. 37, 44 Technological advances in venopulmonary arterial Oxygenators can be useful in the event of severe lung oedema, hypoxia or in patients on ECLS support prior to receiving VAD support. 45 While promising, survival rates with more durable RVAD support systems remain similar to those with BiVAD support. 46, 47 Nonetheless, owing to the novelty of these interventions, improvements in survival and wean rates can be expected with improved patient selection and postoperative management.
Another short-term RVAD option is the Abiomed Impella RP Heart Pump (Impella RP), which uses a 22 Fr catheter-mounted microaxial flow pump ( Figure 3) . It is designed to be implanted percutaneously, using a standard catheterisation procedure via the femoral vein. Blood enters the microaxial pump via the inflow cannula positioned at the inferior vena cava and is delivered directly to the pulmonary artery at a rate of up to 4 l/min, bypassing the RA and the tricuspid and pulmonary valves. The Impella RP is relatively new, and few single-centre studies have reported on outcomes. The prospective RECOVER RIGHT study assessed the safety and benefits of the Impella RP in RVF patients after LVAD implantation as well as after a cardiotomy. 48 The 6-month survival rates were better in the post-LVAD group at approximately 80% compared to approximately 60% in those who had had a cardiotomy.
Although the device is approved for 14 days of temporary RV support, patients required support for an average of only 4 days before successful RV haemodynamic stabilisation and subsequent weaning. 48 The main advantage of the Impella RP is its simple implantation procedure, which allows rapid intervention before RV shock becomes irreversible. There are contraindications, however, which include a body surface area <1.5 m 2 , the presence of mechanical valves, severe valvular stenosis or valvular regurgitation of the tricuspid or pulmonary valve, and other disorders of the pulmonary artery wall that would preclude placement or correct positioning of the Impeller RP device.
Although small studies and anecdotal cases have demonstrated positive outcomes, further investigation is warranted.
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Conclusion
Deciding between univentricular and biventricular support remains complicated. This requires a holistic approach rather than considering isolated markers. Patients should be thoroughly screened and appropriately matched to the device that can yield optimum outcomes.
Patients with evident RVF may be considered for long-term dual VAD therapy for biventricular support. Those with mild signs of RVF may benefit from right-sided temporary percutaneous implantable pumps in the early perioperative period to allow for RV haemodynamic stabilisation.
Where weaning is impossible, temporary BiVADs can serve as a bridge to decision or potential cardiac transplantation in eligible patients.
Early intervention, careful patient and device selection can further improve outcomes in patients in need of BiVAD support and may help bridge the disparity between uni-and biventricular outcomes. n 
